Sergio A. Quezada spends much of his time researching Immunology, T cell, Immunotherapy, Antigen and Immune system. His Immunology research incorporates elements of Blockade and Cancer research, Melanoma. Sergio A. Quezada combines subjects such as CTLA-4 and Antibody with his study of Cancer research.
His study ties his expertise on Cytotoxic T cell together with the subject of T cell. Sergio A. Quezada works mostly in the field of Immunotherapy, limiting it down to topics relating to Monoclonal antibody and, in certain cases, Downregulation and upregulation, K562 cells and Peripheral tolerance, as a part of the same area of interest. His specific area of interest is Antigen, where he studies CD8.
The scientist’s investigation covers issues in Immunology, Immune system, Cancer research, Immunotherapy and T cell. His Immunology study frequently links to related topics such as Blockade. His work carried out in the field of Immune system brings together such families of science as Cancer cell and Cancer.
His Cancer research research is multidisciplinary, relying on both Mutation, Epitope, Antibody, Lung cancer and Effector. Sergio A. Quezada studied Immunotherapy and Melanoma that intersect with Immunogenicity. His T cell study combines topics in areas such as Cytotoxic T cell and CD8, Antigen.
His primary scientific interests are in Cancer research, Immunotherapy, CD8, Immune system and Tumor microenvironment. His Cancer research research includes themes of IL-2 receptor, Phenotype, Antigen, Immunogenicity and Lung cancer. Sergio A. Quezada has included themes like Interleukin 12, Cytotoxic T cell and Cell-mediated cytotoxicity in his Immunotherapy study.
His research integrates issues of T cell, T-cell receptor and Bone marrow in his study of CD8. His T cell research is multidisciplinary, incorporating elements of Acquired immune system and Melanoma. His Immune system study integrates concerns from other disciplines, such as Internal medicine, Evolutionary landscape, Epigenetics and Oncology.
Sergio A. Quezada focuses on Cancer research, Immunotherapy, Antigen, Immune system and CD8. His work deals with themes such as Cytotoxic T cell, Granzyme B, Melanoma, Cell biology and Interleukin 2, which intersect with Immunotherapy. His studies deal with areas such as Cell, Lung cancer, Transcription factor and Interferon as well as Cytotoxic T cell.
His Antigen research includes elements of Tumor microenvironment, Cancer cell, Lymphocyte and Adenocarcinoma. His Immune system study integrates concerns from other disciplines, such as Carcinoma, Pathology and Epigenetics. His CD8 study is concerned with Immunology in general.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan;Nicholas McGranahan;Andrew J. S. Furness;Rachel Rosenthal;Sofie Ramskov.
Tracking the Evolution of Non–Small-Cell Lung Cancer
Mariam Jamal-Hanjani;Gareth A. Wilson;Nicholas McGranahan;Nicolai Juul Birkbak.
The New England Journal of Medicine (2017)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R. Simpson;Fubin Li;Welby Montalvo-Ortiz;Manuel A. Sepulveda.
Journal of Experimental Medicine (2013)
Cutting Edge: Contact-Mediated Suppression by CD4+CD25+ Regulatory Cells Involves a Granzyme B-Dependent, Perforin-Independent Mechanism
David C. Gondek;Li-Fan Lu;Sergio A. Quezada;Shimon Sakaguchi.
Journal of Immunology (2005)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T.A. Chan;M. Yarchoan;E. Jaffee;C. Swanton.
Annals of Oncology (2019)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh;Nicolai J. Birkbak;Nicolai J. Birkbak;Gareth A. Wilson;Gareth A. Wilson;Mariam Jamal-Hanjani.
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
Karl S. Peggs;Sergio A. Quezada;Cynthia A. Chambers;Alan J. Korman.
Journal of Experimental Medicine (2009)
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
Sergio A. Quezada;Tyler R. Simpson;Karl S. Peggs;Taha Merghoub.
Journal of Experimental Medicine (2010)
CD40/CD154 interactions at the interface of tolerance and immunity
Sergio A. Quezada;Lamis Z. Jarvinen;Evan F. Lind;Randolph J. Noelle.
Annual Review of Immunology (2004)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
Nicholas McGranahan;Rachel Rosenthal;Crispin T. Hiley;Crispin T. Hiley;Andrew J. Rowan.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: